GO
Loading...

Pharmaceuticals

More

  • COLUMN-When the best offense is defensive stocks Wednesday, 23 Apr 2014 | 4:30 PM ET

    LONG BEACH, Calif., April 23- You've been on offense with your global stock portfolio for five years, running up the score in sectors like consumer discretionary and technology stocks that have outperformed the broad market. Jamie Doyle, co-manager of the Causeway Global Value Fund, is not ready to make a wholesale switch into defensive plays.

  • LONDON, April 23- The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pharmaceuticals sector and beyond.

  • How Ackman built Allergan stake     Wednesday, 23 Apr 2014 | 12:41 PM ET

    CNBC's Eamon Javers reports on Bill Ackman's stake in Allergan. Javers says this is a classic case of insider trading that is not against the rules.

  • William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

  • US STOCKS-Futures flat after six straight days of gains Wednesday, 23 Apr 2014 | 7:41 AM ET

    *Gilead Sciences rises in premarket after results. *Key earnings on tap; Apple, Facebook out after the close. *Gilead Sciences Inc rose 3.8 percent to $75.60 in heavy premarket trading a day after the drugmaker reported a sharp increase in its quarterly profit, helped by sales of its hepatitis C drug.

  • Ackman: Allergan clear fit for Valeant     Wednesday, 23 Apr 2014 | 7:41 AM ET

    William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.

  • J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.

  • Valeant CEO: Allergan has a great set of assets     Wednesday, 23 Apr 2014 | 7:33 AM ET

    J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

  • Ackman: Valeant fit into Pershing investing mold     Wednesday, 23 Apr 2014 | 7:32 AM ET

    William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.

  • Investor pressure pushing drugmaker M&A deals Wednesday, 23 Apr 2014 | 6:11 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • Investor pressure pushing drugmaker M&A deals Tuesday, 22 Apr 2014 | 6:41 PM ET

    Swiss drugmaker Novartis AG on Tuesday said it's trading its vaccine business for GlaxoSmithKline Plc's cancer drug business and selling its veterinary drug business to Eli Lilly and Co. Meanwhile, Canadian drugmaker Valeant Pharmaceuticals International Inc. said it teamed up with activist investor Bill Ackman in a bid for Botox maker Allergan that could be worth about $45 billion.

  • April 22- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities. Pearson's latest target, with help from activist investor Bill Ackman, is Allergan Inc, maker of anti-wrinkle treatment Botox.

  • Merger mania sweeps Wall Street     Tuesday, 22 Apr 2014 | 5:00 PM ET

    CNBC's Patti Domm discusses the amount of merger activity happening this week with a big three-way deal in the drug industry, and the $46 billion bid by Valeant and activist Bill Ackman for Allergan.

  • Netflix and Harley-Davidson are big market movers Tuesday, 22 Apr 2014 | 4:59 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:. Harley-Davidson Inc., up $4.33 to $71.87. The Interpublic Group of Cos. Inc., up 49 cents to $17.36.

  • Amgen misses 1Q views as higher costs cut profit Tuesday, 22 Apr 2014 | 4:39 PM ET

    Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply. The maker of injected osteoporosis treatment Prolia said Tuesday that net income was $1.07 billion, or $1.40 per share, down from $1.43 billion, or $1.88 per share, in 2013' s first quarter.

  • Show me accretive pharma: O'Leary     Tuesday, 22 Apr 2014 | 4:06 PM ET

    "Shark Tank" investor Kevin O'Leary discusses recent mergers between pharmaceutical companies.

  • Biotech earnings: All eyes on Gilead     Tuesday, 22 Apr 2014 | 3:45 PM ET

    CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.

  • Next big pharma target     Tuesday, 22 Apr 2014 | 2:04 PM ET

    CNBC's Meg Tirrell; Herb Greenberg, CNBC contributor, and Arindam Nag, Mergermarket, discuss potential takeover targets in the pharmaceutical space.

  • US STOCKS-Earnings, healthcare help lift Wall Street Tuesday, 22 Apr 2014 | 2:03 PM ET

    *Netflix up after results, Facebook gains on upgrade. Healthcare, up 1.5 percent, was the best performing of the 10 major S&P sectors, as Allergan Inc jumped 15.8 percent to $164.48 a day after activist investor William Ackman teamed up with Canadian drugmaker Valeant Pharmaceuticals International Inc to bid for the company.

Most Popular Video

Wednesday, 23 Apr 2014 | 10:50 PM ET

Taro Kono, Member of the House of Representatives in Japan's Parliament, says the Liberal Democratic Party (LDP) stands behind Prime Minister Shinzo Abe in pushing for the TPP trade deal.

Wednesday, 23 Apr 2014 | 10:34 PM ET

Charles Li, Chief Executive of Hong Kong Exchanges and Clearing, says the launch of a new commodity trading platform for three metal contracts will facilitate long-term cross-border investments.

Wednesday, 23 Apr 2014 | 10:16 PM ET

David Garrity, Principal at GVA Research, says Apple's decision to raise its dividend and step up its stock buyback program signaled confidence in the tech giant's outlook.